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World Hepatitis Day — July 28, 2019
World Hepatitis Day, observed each year on July 28, was 
established to raise awareness and promote understand-
ing of viral hepatitis around the world. The theme of 
this year’s World Hepatitis Day is “Invest in Eliminating 
Hepatitis,” underscoring the need to increase commitment 
for hepatitis response.  In 2015, an estimated 257 million 
persons were living with hepatitis B and 71 million with 
hepatitis C worldwide (1). 
Persons who inject drugs are at highest risk for hepatitis C 
virus (HCV) infection. Globally, an estimated 15.6 million 
persons aged 15–64 years inject drugs, 52% of whom are 
HCV-antibody positive (2). This issue of MMWR features 
a report on the progress in the country of Georgia toward 
prevention and detection of HCV infection, and linkage 
to treatment, of persons with HCV infection who inject 
drugs (3). Georgia’s hepatitis C elimination program, 
launched in 2015, was recently named the world’s first 
Centre of Excellence in Viral Hepatitis Elimination by 
the European Association for the Study of the Liver 
International Liver Foundation. Access to hepatitis C test-
ing and treatment for persons who inject drugs is critical 
to achieving elimination in countries where persons who 
inject drugs account for a significant proportion of HCV 
infection. Additional information and resources about viral 
hepatitis are available at https://www.cdc.gov/hepatitis.
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In April 2015, the country of Georgia, with a high preva-
lence of hepatitis C virus (HCV) infection (5.4% of the adult 
population, approximately 150,000 persons), embarked on 
the world’s first national elimination program (1,2). Nearly 
40% of these infections are attributed to injection drug use, 
and an estimated 2% of the adult population currently inject 
drugs, among the highest prevalence of injection drug use 
in the world (3,4). Since 2006, needle and syringe programs 
(NSPs) have been offering HCV antibody testing to persons 
who inject drugs and, since 2015, referring clients with positive 
test results to the national treatment program. This report sum-
marizes the results of these efforts. Following implementation 
of the elimination program, the number of HCV antibody 
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tests conducted at NSPs increased from an average of 3,638 
per year during 2006–2014 to an average of 21,551 during 
2015–2018. In 2017, to enable tracking of clinical outcomes 
among persons who inject drugs, NSPs began encouraging 
clients to voluntarily provide their national identification 
number (NIN), which all citizens must use to access health 
care treatment services. During 2017–2018, a total of 2,780 
NSP clients with positive test results for HCV antibody were 
identified in the treatment database by their NIN. Of 494 who 
completed treatment and were tested for HCV RNA ≥12 weeks 
after completing treatment, 482 (97.6%) were cured of HCV 
infection. Following the launch of the elimination program, 
Georgia has made much progress in hepatitis C screening 
among persons who inject drugs; recent data demonstrate high 
cure rates achieved in this population. Testing at NSPs is an 
effective strategy for identifying persons with HCV infection. 
Tracking clients referred from NSPs through treatment comple-
tion allows for monitoring the effectiveness of linkage to care 
and treatment outcomes in this population at high risk, a key 
to achieving hepatitis C elimination in Georgia. The program 
in Georgia might serve as a model for other countries.
The Georgian Harm Reduction Network began operating 
and receiving hepatitis C testing data from NSPs in 2006. As 
of 2016, 16 NSPs were operating in 13 cities across Georgia. 
During 2017–2018, with additional resources provided by the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, two 
additional NSP centers and eight mobile NSP units became 
operational, increasing coverage to approximately 50 of 79 
municipalities countrywide. The Georgian Harm Reduction 
Network also provides diverse services* to persons who inject 
drugs to improve their health outcomes (5).
Persons who inject drugs and who test positive with a rapid 
HCV antibody test at NSPs are offered case management sup-
port and referred to authorized treatment sites for testing to 
confirm active HCV infection.† Since 2017, those persons who 
agree to treatment referral are asked to provide their 11-digit 
NIN to the NSP so that further clinical management can be 
confirmed and documented in the national program treat-
ment database. Once at the treatment center, those patients 
with confirmed infection are enrolled in the treatment pro-
gram and, if eligible for treatment, prescribed a direct-acting 
antiviral regimen according to national treatment guidelines 
(6). Within 12–24 weeks of completing treatment, patients 
are instructed to return to the treatment site for HCV RNA 
testing to determine whether sustained viral response (i.e., 
virologic cure) was achieved. Demographics, diagnostics, and 
treatment outcomes are recorded in real-time in the national 
program treatment database.
For this analysis, program records from the Georgian Harm 
Reduction Network were reviewed to ascertain annual HCV 
* Services provided though the Georgian Harm Reduction Network include 
distribution of sterile injecting equipment, condoms, and naloxone; voluntary 
counselling and testing for hepatitis C, human immunodeficiency virus, 
hepatitis B, and syphilis; peer-to-peer education; raising prevention awareness 
among persons who inject drugs; and advocacy for increased access to NSPs.
† Positive for HCV RNA or HCV core antigen.
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antibody screening and positivity frequencies at NSPs during 
January 2006–December 2018 among persons who inject 
drugs; age group and sex distribution data were available 
from NSPs for 2015–2018. NSPs entered testing and service 
provision data into a database, which were validated by data 
management specialists at the Georgian Harm Reduction 
Network. Deduplication of test results was not conducted 
during 2006–2013 because of insufficient resources; dur-
ing 2014–2018, deduplication of results was performed for 
each calendar year. Data for HCV antibody-positive persons 
who inject drugs who provided their NIN to NSPs during 
January 1, 2017–December 31, 2018, were linked to the 
national program treatment database to ascertain the hepati-
tis C care cascade, which summarizes the sequential steps in 
care. Because this analysis constituted a program evaluation, 
institutional review board oversight was not indicated.
During 2006–2018, NSPs provided 118,943 HCV anti-
body tests to persons who inject drugs, 48,228 (40.5%) of 
which were positive (Figure 1). During the years preceding 
program implementation (2006–2014), 32,738 (average 3,638 
per year) tests were conducted; nearly half (49.6%; 16,247) 
were positive. Following implementation of the elimination 
program (2015–2018), the average number of antibody tests 
performed each year among persons who inject drugs increased 
approximately 500%, to 21,551. Among the 86,205 HCV 
antibody tests provided during this period, 31,981 (37.1%) 
were positive. Males accounted for 96.1% of tests, and persons 
aged 30–39 years were the most frequently tested age group 
(33.7%). In 2018, the HCV antibody prevalence among 
persons aged 18–29 years was 5.5%, the lowest among all 
age groups during 2015–2018. HCV antibody positivity was 
37.8% among males and 24.0% among females tested at NSPs 
during 2015–2018.
During 2017–2018, among 12,163 HCV antibody-positive 
test results from 11,424 clients at NSPs, 2,780 (24.3%) persons 
were identified by their NIN in the national treatment data-
base, 1,626 (58.5%) of whom received a follow-up diagnostic 
test for active HCV infection (Figure 2). Among those tested, 
1,370 (84.3%) had active HCV infection. Of those with active 
infection, 1,029 (75.1%) initiated treatment, 892 (86.7%) of 
whom completed treatment and were eligible for sustained viral 
response testing. Of these, 494 (55.4%) returned for sustained 
viral response testing, 482 (97.6%) of whom achieved cure.
Discussion
Hepatitis C testing at NSPs in Georgia is an effective strategy 
for identifying persons with HCV infection. During the 3 years 
following the launch of the elimination program in Georgia 
in 2015, the number of HCV antibody tests performed at 
NSPs increased nearly fivefold, and the number of persons 
with positive test results doubled, compared with the number 
with positive test results during 2006–2014. Further, voluntary 
FIGURE 1. Number of tests for hepatitis C virus (HCV) antibody conducted and positive test results among persons who inject drugs — Georgian 
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FIGURE 2. Hepatitis C virus (HCV) testing* and treatment outcomes 
among persons who inject drugs referred by needle and syringe 
programs (NSPs) to the national hepatitis C treatment program, as 
identified by their national identification numbers — Georgia, 
2017–2018
HCV antibody-
positive NSP clients 
N = 2,780
n = 1,626 (58.5%)
n = 1,370 (84.3%)
n = 1,029 (75.1%)
n = 892 (86.7%)
n = 494 (55.4%)
n = 482 (97.6%)
Tested positive for active HCV infection
Completed HCV treatment
Initiated HCV treatment
Tested for sustained viral response
Achieved sustained viral response
Received test for active HCV infection
* HCV RNA or HCV core antigen.
use of the NIN among persons who inject drugs and receive 
services at NSPs permitted monitoring the linkage to care and 
treatment, as well as treatment outcomes, among this popula-
tion at high risk. The number of tests performed annually at 
NSPs peaked in 2016, and the percentage of positive test results 
has been trending down since the launch of the elimination 
program in 2015. The reasons for the decrease in testing after 
2016 are unclear but might represent a decreasing pool of 
persons who inject drugs and remain unaware of their HCV 
infection status. The decrease in the proportion of positive 
test results at NSPs during 2016–2018 suggests that a higher 
proportion of persons who inject drugs screened in recent 
years have not yet had exposure to HCV. This interpretation 
is supported by the finding that among all age groups, those 
aged 18–29 years had the lowest HCV antibody positivity 
prevalence in 2018 and might attest to the effectiveness of the 
prevention measures provided by NSPs. Given the estimate of 
approximately 50,000 persons who inject drugs in Georgia and 
that nearly 120,000 HCV antibody tests have been conducted 
at NSPs (with approximately 50,000 positive HCV antibody 
test results) since 2006, it is likely that the majority of persons 
who inject drugs in Georgia have been tested at least once for 
HCV antibody.
Fewer than one fourth of persons who inject drugs agreed to 
provide their NIN to NSPs for the purpose of tracking clinical 
outcomes. Stigma related to drug use and fear of adverse legal, 
social, and economic consequences might discourage persons 
from disclosing their NIN to NSPs before accessing hepatitis C 
care and treatment (6). To avoid revealing their injection drug 
use status in the national registry and treatment database, 
persons could opt to visit treatment sites without divulging 
their affiliation with NSP services. At present, no incentives 
are offered by NSPs to motivate persons to provide their NIN. 
Without the NIN, persons who inject drugs cannot be tracked 
throughout the cascade of hepatitis C care, and the degree to 
which elimination efforts are proceeding in this population is 
hard to ascertain. A study is currently underway to examine 
the feasibility and effectiveness of providing screening, care, 
and treatment services at NSPs.
The findings in this report are subject to at least three 
limitations. First, data from NSP screening and the treatment 
programs could not be independently verified and could be 
subject to data entry errors. Second, resources were unavailable 
to deduplicate NSP test records before 2014; thus, it is not 
known whether each HCV antibody test during 2006–2013 
represented a single person screened. Finally, because only a 
small proportion of screening data from NSPs were linked to 
Summary
What is already known about this topic?
Georgia, with a high prevalence of hepatitis C virus (HCV) 
infection and a high prevalence of injection drug use, launched 
a hepatitis C elimination program in 2015. Since 2006, needle 
and syringe programs (NSPs) have offered HCV antibody testing 
for persons who inject drugs.
What is added by this report?
Following the launch of the hepatitis C elimination program, 
the number of HCV antibody tests performed at NSPs has 
increased fivefold, and the number of persons with positive test 
results has doubled.
What are the implications for public health practice?
Hepatitis C testing at NSPs is an effective strategy for identifying 
persons with HCV infection. The program in Georgia might 
serve as a model for other countries.
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treatment data, this analysis could not fully assess the effective-
ness of linkage from NSP screening to the national care and 
treatment program.
Strategies to engage persons who inject drugs in hepatitis C 
prevention, care, and treatment are needed to ensure elimina-
tion in Georgia. Lessons from Georgia could inform other 
countries with a high prevalence and similar epidemiology of 
hepatitis C.
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